Novoheart Stock Forecast, Price & News

+0.01 (+1.92 %)
(As of 11/20/2020)
Today's Range
50-Day Range
52-Week Range
Volume23,066 shs
Average Volume33,593 shs
Market CapitalizationC$99.98 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVH News and Ratings via Email

Sign-up to receive the latest news and ratings for Novoheart and its competitors with MarketBeat's FREE daily newsletter.

About Novoheart

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Novoheart (CVE:NVH) Frequently Asked Questions

What stocks does MarketBeat like better than Novoheart?

Wall Street analysts have given Novoheart a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novoheart wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Novoheart's stock been impacted by Coronavirus?

Novoheart's stock was trading at C$0.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NVH stock has decreased by 18.5% and is now trading at C$0.53.
View which stocks have been most impacted by COVID-19

Who are Novoheart's key executives?

Novoheart's management team includes the following people:
  • Dr. Ronald Li B.Sc. (Hons), Ph.D., Scientific Co-Founder, CEO & Director (Age 49, Pay $295.17k)
  • Dr. Camie Chan B.S., B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director (Age 46, Pay $312.03k)
  • Prof. Kevin Costa B.S., Ph.D., Chief Scientific Officer & Scientific Co-Founder (Age 54)
  • Prof. Michelle Khine, Scientific Co-Founder & Member of Scientific Advisory Board

Who are some of Novoheart's key competitors?

What other stocks do shareholders of Novoheart own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include Invitae (NVTA) and Natera (NTRA).

What is Novoheart's stock symbol?

Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH."

How do I buy shares of Novoheart?

Shares of NVH and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Novoheart's stock price today?

One share of NVH stock can currently be purchased for approximately C$0.53.

How much money does Novoheart make?

Novoheart has a market capitalization of C$99.98 million and generates C$423,500.00 in revenue each year.

What is Novoheart's official website?

The official website for Novoheart is

How can I contact Novoheart?

The company can be reached via phone at 604-398 3170.

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.